16 completed, 3 terminated, 1 withdrawn. 20 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 20 | Completed 16, Terminated 3, Withdrawn 1 |
| Phase 1 | 4 | Completed 4 |
| Phase 3 | 1 | Completed 1 |
Follow Asperger Syndrome: new trials by email Literature Review of Asperger Syndrome trials Research Report on Asperger Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents Latuda© - Schizophrenia, Schizoaffective Disorder | Phase 2 | Completed | University of North Carolina, Chapel Hill | 9 | 2012-12-01 | 2017-06-14 |
| Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Memantine Hydrochloride (HCl) - Autism Spectrum Disorder (ASD), Autism | Phase 2 | Terminated | Forest Laboratories | 747 | 2012-10-01 | 2015-02-16 |
| Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine Memantine Hydrochloride (HCl), Placebo capsules - Autistic Disorder, Autism | Phase 2 | Completed | Forest Laboratories | 479 | 2012-09-01 | 2019-04-24 |
| An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Memantine Hydrochloride (HCl) - Autism Spectrum Disorder (ASD), Autism | Phase 2 | Completed | Forest Laboratories | 906 | 2012-06-01 | 2014-08-07 |
| A Folinic Acid Intervention for Autism Spectrum Disorders Folinic Acid and placebo, Folinic Acid - Autism Spectrum Disorder, Autistic Disorder | Phase 2 | Terminated | University of Arkansas | 99 | 2012-05-01 | 2017-10-17 |
| Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders Arbaclofen - Autism Spectrum Disorders | Phase 2 | Completed | Seaside Therapeutics, Inc. | 150 | 2011-05-01 | 2013-07-31 |
| Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders Cognitive-behavioral therapy, Treatment as Usual - Autism, Asperger's Syndrome | Phase 2 / Phase 3 | Completed | University of South Florida | 45 | 2010-04-01 | 2013-04-02 |
| Cognitive Behavioral Therapy (CBT) for Anxiety Disorders in Autism: Adapting Treatment for Adolescents Cognitive-Behavioral Therapy, Wait-list - Anxiety Disorders in Youth With Autism, Asperger's Syndrome, and Pervasive Developmental Disorder Not Otherwise Specified | Phase 1 / Phase 2 | Completed | University of South Florida | 33 | 2009-11-01 | 2014-07-01 |
| Cholesterol in ASD: Characterization and Treatment Cholesterol - Autism, Asperger Disorder | Phase 1 / Phase 2 | Completed | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 44 | 2009-07-28 | 2018-07-05 |
| My Scrivener® - Measuring Effectiveness and Dose Response in Children My Scrivener(R) - Asperger's Syndrome, Dyslexia | Phase 1 / Phase 2 | Completed | Obslap Research LLC | 176 | 2009-04-01 | 2010-10-28 |
| Transcranial Magnetic Stimulation for Evaluation and Treatment of Repetetive Behaviors in Autism transcranial magnetic stimulation - Autism, Asperger Disorder | Phase 2 | Terminated | New York State Psychiatric Institute | 10 | 2008-11-01 | 2017-03-24 |
| A Study of Oral N-Acetylcysteine in Children With Autism Spectrum Disorders N-acetylcysteine, Placebo - Autistic Disorder, Asperger Syndrome | Phase 2 | Completed | Indiana University | 31 | 2007-03-01 | 2017-06-14 |
| Mercury Chelation to Treat Autism DMSA - Autism, Asperger's Disorder | Phase 2 | Withdrawn | National Institute of Mental Health (NIMH) | 2006-09-01 | 2013-09-18 | |
| The Development of Autistic Children Based on Mothers´Response in Autism Behavior Checklist Speech Therapy - Autism, Asperger Syndrome | Phase 1 / Phase 2 | Completed | Federal University of São Paulo | 11 | 2006-03-01 | 2008-08-01 |
| An Open-Label Trial of Aripiprazole in Autism Spectrum Disorders Aripiprazole - Autism, Asperger's Disorder | Phase 2 | Completed | Cambridge Health Alliance | 14 | 2006-02-01 | 2017-02-15 |
| Study of Aripiprazole to Treat Children and Adolescents With Autism aripiprazole - Autistic Disorder, Asperger Syndrome | Phase 2 | Completed | University of North Carolina, Chapel Hill | 30 | 2006-01-01 | 2014-03-26 |
| Riluzole to Treat Child and Adolescent Obsessive-Compulsive Disorder With or Without Autism Spectrum Disorders Riluzole, Placebo - Obsessive-Compulsive Disorder, Autism Spectrum Disorder | Phase 2 | Completed | National Institute of Mental Health (NIMH) | 78 | 2005-08-01 | 2014-07-15 |
| A Study of Aripiprazole in Children and Adolescents With Aspergers and Pervasive Developmental Disorder. aripiprazole - Asperger's Disorder, Pervasive Developmental Disorder | Phase 2 | Completed | Indiana University | 25 | 2005-01-01 | 2014-06-04 |
| CBT for Comorbid Anxiety Disorders in Children With Autism, Asperger Syndrome, or PDD-NOS Cognitive-behavioral therapy - Autistic Disorder, Asperger Syndrome | Phase 2 | Completed | University of California, Los Angeles | 20 | 2005-01-01 | 2012-04-02 |
| Citalopram for Children With Autism and Repetitive Behavior (STAART Study 1) citalopram hydrobromide, placebo - Autistic Disorder | Phase 2 | Completed | Boston University | 149 | 2004-04-01 | 2017-03-10 |
Autistic Disorder (18) · Autism Spectrum Disorder (10) · Child Development Disorders, Pervasive (8) · Anxiety Disorders (3) · Obsessive-Compulsive Disorder (3) · Aggression (2) · Anxiety, Separation (1) · Attention Deficit Disorder with Hyperactivity (1) · Behavioral Symptoms (1) · Bipolar Disorder (1) · Brain Injuries, Traumatic (1) · Cerebral Palsy (1) · Ceremonial Behavior (1) · Compulsive Behavior (1)
Neurodevelopmental Disorders (20) · Mental Disorders (19) · Child Development Disorders, Pervasive (12) · Autism Spectrum Disorder (10) · Behavior (3) · Social Behavior (3) · Aberrant Motor Behavior in Dementia (2) · Abnormalities, Multiple (1) · Anxiety Disorders (1) · Attention Deficit and Disruptive Behavior Disorders (1) · Behavioral Symptoms (1) · Bipolar and Related Disorders (1) · Brain Damage, Chronic (1) · Brain Diseases (1) · Brain Injuries (1)
Aripiprazole (3) · Cognitive Behavioral Therapy (3) · Memantine (3) · Acetylcysteine (1) · Cholesterol (1) · Citalopram (1) · Counseling (1) · Implosive Therapy (1) · Leucovorin (1) · Lurasidone Hydrochloride (1) · Psychotherapy (1) · Riluzole (1) · Speech Therapy (1) · Succimer (1) · Therapeutics (1)
Forest Laboratories (3) · Indiana University (2) · National Institute of Mental Health (NIMH) (2) · University of North Carolina, Chapel Hill (2) · University of South Florida (2) · Boston University (1) · Cambridge Health Alliance (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · Federal University of São Paulo (1) · New York State Psychiatric Institute (1) · Obslap Research LLC (1) · Seaside Therapeutics, Inc. (1) · University of Arkansas (1) · University of California, Los Angeles (1)
United States (19) · Belgium (3) · Colombia (3) · Estonia (3) · France (3) · Hungary (3) · Iceland (3) · Italy (3) · New Zealand (3) · Poland (3) · Serbia (3) · South Africa (3) · South Korea (3) · Spain (3) · Ukraine (3)
Jordan Lateiner, MS, MBA (3) · Linmarie Sikich, MD (2) · Alexandra Sporn, MD (1) · Ana Carina Tamanaha, Student (1) · Bryan King, MD (1) · Eric A Storch, Ph.D. (1) · Eric Storch, PhD (1) · Forbes D Porter, M.D. (1) · Jean A Frazier, MD (1) · Jeffrey J Wood, Ph.D. (1) · Kimberly A. Stigler, MD (1) · Martin H. Plawecki, M.D. (1) · Richard E Frye, M.D./Ph.D. (1) · Susan E Palsbo, PhD (1) · Susan E Swedo, MD (1)
PMID 37811711, PMID 36006807, PMID 18315448, PMID 19309326, PMID 19487623, PMID 23106988, PMID 23357440, PMID 24061784, PMID 24356715, PMID 25526831, PMID 27752075, PMID 34693989
R34HD065274 (1), U54MH066398 (1)